Related Experiment Video

Updated: Jun 29, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Defining a Subgroup of Myelodysplastic Syndrome Patients With Very Poor-Risk Cytogenetics Demonstrating a Relatively

Xavier Poiré1, Dirk-Jan Eikema2, Linda Koster3

  • 1Institut Roi Albert II, Cliniques Universitaires St-Luc, Brussels, Belgium.

American Journal of Hematology
|June 28, 2026
PubMed
Abstract

No abstract available in PubMed .

Keywords:
allogeneic stem cell transplantationmyelodysplastic syndromeoutcomespoor‐risk cytogenetics

More Related Videos

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
06:28

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

Related Experiment Videos

Last Updated: Jun 29, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
06:28

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Articles linked to this work by shared authors, journal, and citation graph.

Interindividual HLA evolutionary divergence in mismatched unrelated donor allo-HCT for malignant hematological disorders.

Blood advances·2026

An Italian cartography of VEXAS-related thrombosis.

HemaSphere·2026

Defining global priorities in hematopoietic transplantation and cellular therapy: a statement paper from EBMT Global Committee.

Bone marrow transplantation·2026

Multilineage lymphoid clonal hematopoiesis: a cross-sectional, correlative analysis of plasma cell dyscrasias and large granular lymphocytic leukemia.

Leukemia·2026

Real-world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS-like tyrosine kinase 3 (FLT3)-mutated relapsed/refractory acute myeloid leukaemia: A UK single-centre experience.

British journal of haematology·2026

Comprehensive analysis of prognostic factors in myelodysplastic syndromes with isolated deletion of chromosome 5q.

Blood advances·2026

Splenic Tropism and Spleen-Modulated Systemic Inflammation in Acute Plasmodium vivax Malaria.

American journal of hematology·2026

The Presence and Percentage of Circulating Nucleated Red Blood Cells Reveal Distinct Characteristics in Adults With Sickle Cell Disease.

American journal of hematology·2026

Anticoagulant Therapy and Bleeding-Related Hospitalizations in Patients With Cancer: A National Cohort Study.

American journal of hematology·2026

Phase II Study of Posttransplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After HLA-Mismatched Unrelated Donor Reduced Intensity Transplantation: Results From the ACCESS Trial Expansion Cohort.

American journal of hematology·2026

Primary Plasma Cell Leukemia.

American journal of hematology·2026

Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: The PETHRATIFY Study.

American journal of hematology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us